Aquila Atlantis Hotel,
Heraklion, Crete, 03-06 November 2022
IASIS PHARMA participated at the 29th Panhellenic Conference of the Hellenic Society for the Study of Bone Metabolism, held in Heraklion, Crete, at the Aquila Atlantis Hotel, from November 3 to 6, 2022.
The purpose of the 29th H.S.S.B.M. Panhellenic Conference was to cover the newest developments in the subjects of metabolic bone diseases as full as possible, by presenting research papers related to the subject.
At IASIS PHARMA exhibition stand, the following products were presented:
COVED®: Alendronic Acid 70mg / cholecalciferol 5.600IU, indicated for the treatment of postmenopausal osteoporosis in women who do not take vitamin D supplementation and are at risk of vitamin D deficiency.
Etrozac®: Etoricoxib, indicated for the relief of the symptoms of osteoarthritis (OA), rheumatoid arthritis (RA), ankylosing spondylitis, pain and symptoms of inflammation associated with acute gout.
Etrozac® is available in packages of 14 or 20 film coated tablets, in a wide dosage range:
Etrozac® 20 tabs x 60 mg
Etrozac® 14 tabs x 90 mg
Etrozac® 20 tabs x 90 mg
Etrozac® 20 tabs x 120 mg
